相关实验视频
Updated: Mar 11, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.6K
超越线性和静态风险:重新评估扩散大B细胞淋巴瘤的核心预后因素
Rashad Ismayilov1,2, Murat Ozdede3, Yahya Büyükaşık4
1Faculty of Medicine, Department of Medical Oncology, Baskent University, Ankara, Türkiye.
Expert review of hematology
|March 9, 2026
概括
随着时间的推移,扩散性大B细胞淋巴瘤 (DLBCL) 的预后因素发生变化,影响早期和晚期的生存率不同. 需要新的模型来捕捉这些动态,非线性效应,以进行个性化风险评估.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 生物统计学 生物统计学
背景情况:
- 扩散型大B细胞淋巴瘤 (DLBCL) 的传统预后模型,就像国际预后指数 (IPI) 一样,假设静态和线性风险因素影响.
- 这些假设可能不准确地反映DLBCL患者结果的复杂性和时间变化.
研究的目的:
- 研究已确定的风险因素对使用R-CHOP治疗的DLBCL患者的存活期的时间依赖和非线性影响.
- 挑战当前预后指数的静态性质,并倡导动态模型.
主要方法:
- 对664名接受R-CHOP化疗的DLBCL患者的分析.
- 利用受限立方脊柱建模来评估预后因素和整体存活率之间的非线性关系.
- 研究了个别风险因素预测能力的时间演变.
主要成果:
- 国际预测指数 (IPI) 显示总体稳定,但个别组件有动态变化.
- ECOG性能评分,β-2微球蛋白 (β2M) 和乳酸脱酶 (LDH) 预测了早期死亡率,但随着时间的推移而减少.
- 安阿伯阶段和外节参与对于后来的风险预测变得更加重要,β2M在两年后出现复苏.
- 在总生存率和年龄,LDH和β2M之间观察到显著的非线性关系 (p < 0.001对于非线性).
结论:
- 在DLBCL的基线因素的预后影响是动态和非线性,而不是静态.
- 当前的风险评分可能会过分简化患者的预后,因为它不考虑时间变化.
- 未来的DLBCL预后模型应纳入这些依赖时间和非线性动态,以改善个性化的风险分层.
相关概念视频
01:21Cancer Survival Analysis
808
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
808
02:07Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
02:56Treatment Resistant Cancers
3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
01:24B Cell Activation and Differentiation
17.7K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
17.7K
01:21Factors Affecting Drug Response: Overview
3.2K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.2K
01:29Therapeutic Drug Monitoring: Affecting Factors
307
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
307